Antithrombin III injection via the portal vein suppresses liver damage

World Journal of Gastroenterology

Volumn 18, Issue 16, 2012, Pages 1884-1891

  Miyazaki, Masayuki ^a   Kato, Masaki ^a   Tanaka, Masatake ^a   Tanaka, Kosuke ^a   Takao, Shinichiro ^a   Kohjima, Motoyuki ^a,b   Ito, Tetsuhide ^a   Enjoji, Munechika ^a,c   Nakamuta, Makoto ^a,b   Kotoh, Kazuhiro ^a   Takayanagi, Ryoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

Author keywords

Acute liver failure; Antithrombin III; Intravascular coagulation; Portal vein

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHROBIN P500; ANTITHROMBIN III; FIBRIN; FIBRIN DEGRADATION PRODUCT; GALACTOSAMINE; HEME OXYGENASE 1; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE LIVER FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; HISTOPATHOLOGY; INJECTION; LIVER CELL; MALE; NONHUMAN; PORTAL VEIN; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84860491081     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i16.1884     Document Type: Article

References (38)

1. Starzl TE, Iwatsuki S, Van Thiel DH, Gartner JC, Zitelli BJ, Malatack JJ, Schade RR, Shaw BW, Hakala TR, Rosenthal JT, Porter KA. Evolution of liver transplantation. Hepatology 1982; 2: 614-636
2. Carpentier B, Gautier A, Legallais C. Artificial and bioartificial liver devices: present and future. Gut 2009; 58: 1690-1702
3. McKenzie TJ, Lillegard JB, Nyberg SL. Artificial and bioartificial liver support. Semin Liver Dis 2008; 28: 210-217
4. Rake MO, Flute PT, Pannell G, Williams R. Intravascular coagulation in acute hepatic necrosis. Lancet 1970; 1: 533-537
5. Fujiwara K, Ogata I, Ohta Y, Hirata K, Oka Y, Yamada S, Sato Y, Masaki N, Oka H. Intravascular coagulation in acute liver failure in rats and its treatment with antithrombin III. Gut 1988; 29: 1103-1108
6. Mochida S, Ogata I, Hirata K, Ohta Y, Yamada S, Fujiwara K. Provocation of massive hepatic necrosis by endotoxin after partial hepatectomy in rats. Gastroenterology 1990; 99: 771-777
7. Nakamura K, Ito T, Yoneda M, Takamoto S, Nakade Y, Okamoto S, Okada M, Yokohama S, Aso K, Makino I. Antithrombin III prevents concanavalin A-induced liver injury through inhibition of macrophage inflammatory protein-2 release and production of prostacyclin in mice. J Hepatol 2002; 36: 766-773
8. Yamada S, Ogata I, Hirata K, Mochida S, Tomiya T, Fujiwara K. Intravascular coagulation in the development of massive hepatic necrosis induced by Corynebacterium parvum and endotoxin in rats. Scand J Gastroenterol 1989; 24: 293-298
9. Lin CP, Yu HC, Cheng JS, Lai KH, Lo GH, Hsu PI, Lin CK, Chen HH, Lo CC, Liang HL, Tseng HH. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma. J Chin Med Assoc 2004; 67: 602-610
10. Kotoh K, Enjoji M, Nakamuta M, Yoshimoto T, Kohjima M, Morizono S, Yamashita S, Horikawa Y, Yoshimitsu K, Tajima T, Asayama Y, Ishigami K, Hirakawa M. Arterial steroid injection therapy can inhibit the progression of severe acute hepatic failure toward fulminant liver failure. World J Gastroenterol 2006; 12: 6678-6682
11. Higuchi N, Kato M, Kotoh K, Kohjima M, Aishima S, Nakamuta M, Fukui Y, Takayanagi R, Enjoji M. Methylprednisolone injection via the portal vein suppresses inflammation in acute liver failure induced in rats by lipopolysaccharide and d-galactosamine. Liver Int 2007; 27: 1342-1348
12. Puchtler H, Waldrop FS, Meloan SN. On the mechanism of Mallory's phosphotungstic acid-haematoxylin stain. J Microsc 1980; 119: 383-390
13. Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer. Proc Natl Acad Sci USA 1994; 91: 6496-6500
14. Kay HH, Zhu S, Tsoi S. Hypoxia and lactate production in trophoblast cells. Placenta 2007; 28: 854-860
15. Shi LB, Huang JH, Han BS. Hypoxia inducible factor-1alpha mediates protective effects of ischemic preconditioning on ECV-304 endothelial cells. World J Gastroenterol 2007; 13: 2369-2373
16. Kourembanas S. Hypoxia and carbon monoxide in the vasculature. Antioxid Redox Signal 2002; 4: 291-299
17. Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, Jiang BH, Leung S, Roe R, Wiener C, Yu A. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 1997; 51: 553-555
18. Kotoh K, Enjoji M, Kato M, Kohjima M, Nakamuta M, Takayanagi R. A new parameter using serum lactate dehydrogenase and alanine aminotransferase level is useful for predicting the prognosis of patients at an early stage of acute liver injury: a retrospective study. Comp Hepatol 2008; 7: 6
19. Fujii H, Takahashi T, Matsumi M, Kaku R, Shimizu H, Yokoyama M, Ohmori E, Yagi T, Sadamori H, Tanaka N, Akagi R, Morita K. Increased heme oxygenase-1 and decreased delta-aminolevulinate synthase expression in the liver of patients with acute liver failure. Int J Mol Med 2004; 14: 1001-1005
20. Ganey PE, Luyendyk JP, Newport SW, Eagle TM, Maddox JF, Mackman N, Roth RA. Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. Hepatology 2007; 46: 1177-1186
21. Ohta S, Nakamuta M, Fukushima M, Kohjima M, Kotoh K, Enjoji M, Nawata H. Beraprost sodium, a prostacyclin (PGI) analogue, ameliorates concanavalin A-induced liver injury in mice. Liver Int 2005; 25: 1061-1068
22. Seto S, Kaido T, Yamaoka S, Yoshikawa A, Arii S, Nakamura T, Niwano M, Imamura M. Hepatocyte growth factor prevents lipopolysaccharide-induced hepatic sinusoidal endothelial cell injury and intrasinusoidal fibrin deposition in rats. J Surg Res 1998; 80: 194-199
23. Mochida S, Arai M, Ohno A, Yamanobe F, Ishikawa K, Matsui A, Maruyama I, Kato H, Fujiwara K. Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats. Hepatology 1999; 29: 1532-1540
24. Matsui A, Mochida S, Ohno A, Nagoshi S, Hirose T, Fujiwara K. Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol Res 2004; 29: 202-206
25. Le Bail B, Bioulac-Sage P, Senuita R, Quinton A, Saric J, Balabaud C. Fine structure of hepatic sinusoids and sinusoidal cells in disease. J Electron Microsc Tech 1990; 14: 257-282
26. Arai M, Mochida S, Ohno A, Ogata I, Obama H, Maruyama I, Fujiwara K. Blood coagulation equilibrium in rat liver microcirculation as evaluated by endothelial cell thrombomodulin and macrophage tissue factor. Thromb Res 1995; 80: 113-123
27. Hirata K, Ogata I, Ohta Y, Fujiwara K. Hepatic sinusoidal cell destruction in the development of intravascular coagulation in acute liver failure of rats. J Pathol 1989; 158: 157-165
28. Yamanobe F, Mochida S, Ohno A, Ishikawa K, Fujiwara K. Recombinant human tissue factor pathway inhibitor as a possible anticoagulant targeting hepatic sinusoidal walls. Thromb Res 1997; 85: 493-501
29. Fujiwara K, Okita K, Akamatsu K, Abe H, Tameda Y, Sakai T, Inoue N, Kanai K, Aoki N, Oka H. Antithrombin III concentrate in the treatment of fulminant hepatic failure. Gastroenterol Jpn 1988; 23: 423-427
30. Langley PG, Hughes RD, Forbes A, Keays R, Williams R. Controlled trial of antithrombin III supplementation in fulminant hepatic failure. J Hepatol 1993; 17: 326-331
31. Inthorn D, Hoffmann JN, Hartl WH, Mühlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock 1997; 8: 328-334
32. Inthorn D, Hoffmann JN, Hartl WH, Mühlbayer D, Jochum M. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock 1998; 10: 90-96
33. Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Hemost 1998; 24: 27-32
34. Oelschläger C, Römisch J, Staubitz A, Stauss H, Leithäuser B, Tillmanns H, Hölschermann H. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002; 99: 4015-4020
35. Hagiwara S, Iwasaka H, Matsumoto S, Noguchi T. High dose antithrombin III inhibits HMGB1 and improves endotoxin- induced acute lung injury in rats. Intensive Care Med 2008; 34: 361-367
36. Dunzendorfer S, Kaneider N, Rabensteiner A, Meierhofer C, Reinisch C, Römisch J, Wiedermann CJ. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood 2001; 97: 1079-1085
37. Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 2002; 16: 1151-1162
38. Farombi EO, Surh YJ. Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. J Biochem Mol Biol 2006; 39: 479-491